News & Events about Assertio Holdings Inc.
SYMPAZAN (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN delivers clobazam to LGS patients with no crushing, no mixing, no prep work LAKE FOREST, Ill., Jan. 17, 2023 (GLOBE ...
Globe Newswire
3 months ago
WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients problems through simplifying complex delivery methods, announced today a transaction to license Sympazan (clobazam) oral film to...
Globe Newswire
3 months ago
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a specialty pharmaceutical company offering...
RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor...
Globe Newswire
4 months ago
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, will host investor meetings September 14, 2022 as part ...